More Western Hypercholesterolemic Patients Achieve Japan Atherosclerosis Society LDL-C Goals with Rosuvastatin Therapy Than with Atorvastatin, Pravastatin, or Simvastatin Therapy

Circulation Journal

Volumn 68, Issue 2, 2004, Pages 107-113

  Strutt, Kristina ^a   Caplan, Richard ^a   Hutchison, Howard ^a   Dane, Aaron ^a   Blasetto, James ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Atherosclerosis; Guidelines; HMG CoA reductase inhibitors; Hypercholesterolemia treatment

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CONTINENTAL POPULATION GROUPS; DRUG EVALUATION; EUROPE; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; JAPAN; MALE; MIDDLE AGED; MULTICENTER STUDIES; PRAVASTATIN; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS; SIMVASTATIN; SULFONAMIDES; TREATMENT OUTCOME; UNITED STATES;

EID: 1042279592     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.107     Document Type: Article

References (34)

1. Japan Atherosclerosis Society. Japan Atherosclerosis Society (JAS) guidelines for diagnosis and treatment of atherosclerotic cardiovascular disease. Tokyo: JAS, 2002.
2. Investigating Committee of Guidelines for Diagnosis and Treatment of Hyperlipidemia in Adults. Guideline for diagnosis and treatment of Hyperlipidemia. J Jpn Atheroscler Soc 1997; 25: 1-34.
3. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
4. European Atherosclerosis Society. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-1503.
5. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-213.
6. Saito Y, Goto Y, Dane A, Strutt K. Randomized, double-blind, placebo-controlled, dose-ranging study of rosuvastatin in Japanese hypercholesterolemic subjects (abstract). Atherosclerosis 2002; 3: 199.
7. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001; 88: 504-508.
8. Olsson AG, McTaggart F, Raza A. Rosuvastatin: A highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002; 20: 303-328.
9. Yamamoto A, Arakawa K, Sasaki J, Matsuzawa Y, Takemura K, Tsushima M, et al for the Rosuvastatin Dose-Ranging Trials Group. Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: An early phase II study. J Atheroscler Thromb 2002; 9: 48-56.
10. Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002; 89: 268-275.
11. Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002; 144: 1044-1051.
12. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double-blind study. J Cardiovasc Risk 2001; 8: 383-390.
13. Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, et al for the Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial. Am Heart J 2002; 144: 1036-1043.
14. Stein E, Strutt KL, Miller E, Southworth H. Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolemia (abstract). Atherosclerosis 2001; 2: 90.
15. Blasetto J, Stein E, Brown V, Chitra R, Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemia patients and in special population groups. Am J Cardiol 2003; 91(Suppl): 3C-10C.
16. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
17. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
18. Sacks FM, Moye LA, Davis BRA, Cole TG, Rouleau JL, Nash DT, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998; 97: 1446-1452.
19. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
21. Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, et al for the J-LIT Study Group. Japan Lipid Intervention Trial: Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: Secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002; 66: 1096-1100.
22. Saito Y, Goto Y, Yasugi T, Hata Y, Nakaya N, Nakashima M. Clinical effect of fluvastatin (XU62-320) on hyperlipidemia: Double-blind comparative dose-finding study in three parallel groups. Rinsyo-iyaku 1995; 11(Suppl 1): 153-180.
23. Matsuzawa Y, Kita T, Mabuchi H, Matsuzaki M, Nakaya N, Oikawa S, et al for the J-LIT Study Group. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J 2003; 67: 287-294.
24. Kobayashi T, Homma Y. Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3. J Clin Pharmacol 2001; 41: 1055-1058.
25. Ito H, Ouchi Y, Ohashi Y, Saito Y, Ishikawa T, Nakamura H, et al. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: The Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE). J Atheroscler Thromb 2001; 8: 33-44.
26. Sasaki J, Arakawa K, Iwashita M, Matsushita Y, Kono S, Kyushu Lipid Intervention Study (KLIS) Group. Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men: The Kyushu Lipid Intervention Study. Circ J 2003; 67: 473-478.
27. Knatterud L, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, et al for the Post CABG Investigators. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the Post Coronary Artery Bypass Graft Trial. Circulation 2000; 102: 157-165.
28. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153-162.
29. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70-76.
30. Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering therapy: Projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002; 105: 152-156.
31. Pearson T, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP). Arch Intern Med 2000; 160: 459-467.
32. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001; 111: 185-191.
33. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996; 100: 605-610.
34. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med 1996; 100: 197-204.